Richard Deming
Expertise in
39
conditions

Dr. Richard Deming

Radiation Oncology
Mercy Therapeutic Radiology Associates LLC
411 Laurel St Ste C100, 
Des Moines, IA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
39
conditions
Mercy Therapeutic Radiology Associates LLC
411 Laurel St Ste C100, 
Des Moines, IA 

Overview

Richard Deming is a Radiation Oncologist practicing medicine in Des Moines, Iowa.

Dr. Deming is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Colorectal Cancer, Astrocytoma, Gamma Knife Radiosurgery, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 8 peer reviewed articles and participating in 145 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in IA

Hospital Affiliations

Mercyone Des Moines Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
Sanford Health
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 7 Less Insurance Carriers -

Locations

Mercy Therapeutic Radiology Associates LLC
411 Laurel St Ste C100, Des Moines, IA 50314

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

143 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Implementation and Effectiveness Trial of HN-STAR
Implementation and Effectiveness Trial of HN-STAR
Enrollment Status: Active_not_recruiting
Publish Date: April 15, 2026
Intervention Type: Other
Study Phase: Not Applicable
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: April 14, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Talazoparib
Study Phase: Phase 2
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Enrollment Status: Suspended
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Biological, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nab-paclitaxel, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

8 Total Publications

Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation.
Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation.
Journal: European urology oncology
Published: October 31, 2022
Similar Doctors
Expertise in
25
conditions
Dr. John Martens
Radiation Oncology
Expertise in
25
conditions
Dr. John Martens
Radiation Oncology

Mercy Therapeutic Radiology Associates LLC

411 Laurel St Ste C100, 
Des Moines, IA 
 (0.7 miles away)
515-643-8780
Languages Spoken:
English
See accepted insurances

John Martens is a Radiation Oncologist practicing medicine in Des Moines, Iowa. Dr. Martens is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Laryngeal Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Endometrial Cancer.

Expertise in
13
conditions
Dr. John Triantafyllos
Radiation Oncology
Expertise in
13
conditions
Dr. John Triantafyllos
Radiation Oncology

Central Iowa Hospital Corporation

1221 Pleasant St Ste A100, 
Des Moines, IA 
 (0.9 miles away)
515-241-4330
Languages Spoken:
English
See accepted insurances

John Triantafyllos is a Radiation Oncologist practicing medicine in Des Moines, Iowa. Dr. Triantafyllos is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Familial Prostate Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Prostate Cancer.

Expertise in
13
conditions
Dr. George Voynov
Radiation Oncology
Expertise in
13
conditions
Dr. George Voynov
Radiation Oncology

Mercy Therapeutic Radiology Associates LLC

411 Laurel St Ste C100, 
Des Moines, IA 
 (0.7 miles away)
515-643-8780
Languages Spoken:
English
See accepted insurances

George Voynov is a Radiation Oncologist practicing medicine in Des Moines, Iowa. Dr. Voynov is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), Lung Cancer, and Gamma Knife Radiosurgery.

Frequently Asked Questions about Dr. Richard Deming

How do I make an appointment with Dr. Richard Deming?

You can book an appointment with Dr. Richard Deming by calling their office at 515-643-8780. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Richard Deming a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Richard Deming is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Richard Deming specialize in?

While Dr. Richard Deming is a Radiation Oncology, they have specific expertise in Lung Cancer, Colorectal Cancer, and Astrocytoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Richard Deming participate in research or clinical trials?

Yes. Dr. Richard Deming has published 8 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Richard Deming's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Richard Deming accept my insurance?

Dr. Richard Deming accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 515-643-8780 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Deming's expertise for a condition
ConditionClose
    View All 15 Distinguished Conditions
    View All 24 Advanced Conditions
    View All 99 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile